

---

# Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action



Jade G. M. Logger, MD,<sup>a</sup> Jill I. Olydam, MD,<sup>b</sup> and Rieke J. B. Driessen, MD, PhD<sup>a</sup>  
*Nijmegen and Rotterdam, The Netherlands*

**Background:** Flushing and erythema are frequent skin symptoms in rosacea. Because their adequate treatment remains a clinical challenge, new treatment options are explored, such as oral  $\beta$ -blockers.

**Objectives:** To evaluate the efficacy of oral  $\beta$ -blockers for rosacea-associated facial flushing and erythema.

**Methods:** PubMed, Embase, Web of Science, and Cochrane Library were systematically searched, including studies providing original data on the efficacy of oral  $\beta$ -blockers in rosacea patients with facial flushing and/or persistent erythema. Risk of bias was assessed using the Cochrane Risk of Bias tool, Newcastle-Ottawa scale, and Quality in Prognosis Studies tool.

**Results:** Nine studies evaluating the use of carvedilol, propranolol, nadolol, and  $\beta$ -blockers in general were included. Articles studying carvedilol and propranolol showed a large reduction of erythema and flushing during treatment with a rapid onset of symptom control. Bradycardia and hypotension were the most commonly described adverse events.

**Limitations:** Most studies had a retrospective design with a small sample size, and outcome measurement was often subjective.

**Conclusions:** Oral  $\beta$ -blockers could be an effective treatment option for patients with rosacea with facial erythema and flushing that does not respond to conventional therapy. Larger prospective trials with objective outcome assessment are needed to validate the promising results of these studies. (J Am Acad Dermatol 2020;83:1088-97.)

**Key words:** carvedilol; beta-adrenergic blockers; facial erythema; flushing; nadolol; propranolol; rosacea; systematic review.

Flushing and persistent erythema are common rosacea symptoms.<sup>1,2</sup> In contrast to effective treatment options targeting inflammation in

rosacea, diminishing erythema and flushing remains a clinical challenge.<sup>3,4</sup> The etiology of increased blood flow in rosacea is complex and probably

---

From the Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands<sup>a</sup>; and Department of Dermatology, Erasmus University, Rotterdam, The Netherlands.<sup>b</sup>

Funding sources: None.

Conflicts of interest: Dr Logger has received research funding from Galderma; carried out clinical trials for AbbVie, Novartis, Janssen, and LEO Pharma; and received reimbursement for attending meetings from AbbVie. Dr Olydam carries out clinical trials for AbbVie and Novartis. Dr. Driessen has received research funding from Galderma; carried out clinical trials for Cutanea Life Sciences, Galderma, AbbVie, Novartis, and Janssen; received reimbursement for attending meetings from AbbVie and Galderma; and has served as a consultant for AbbVie, Galderma, and Novartis; fees were paid directly to the institution.

---

IRB approval status: Not applicable.

Accepted for publication April 21, 2020.

Reprints not available from the authors.

Correspondence to: Jade G.M. Logger, MD, Department of Dermatology, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: [Jade.Logger@radboudumc.nl](mailto:Jade.Logger@radboudumc.nl).

Published online April 29, 2020.

0190-9622

© 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.jaad.2020.04.129>

multifactorial; both vessel dilation and neuronal, inflammatory, and hormonal pathways, which can be enhanced by various external triggers, seem to be involved.<sup>5-7</sup> The only approved treatments for facial erythema in rosacea are topical brimonidine and oxymetazoline, 2 selective  $\alpha$ -adrenergic receptor agonists.<sup>8-10</sup> Although effective in some cases, poor response and rebound erythema are common, especially for brimonidine.<sup>10-15</sup> Their vasomotor target is, however, interesting, resulting in local vasoconstriction. Because skin appearance has a significant impact on quality of life, the importance of new approaches for facial erythema and flushing has become clear.<sup>16-18</sup>

A possible therapeutic option not yet approved for persistent erythema and flushing is treatment with oral  $\beta$ -blockers, which antagonize the effects of sympathetic nerve stimulation and circulating endogenous catecholamines at adrenoceptors.<sup>19,20</sup> Three types of adrenoceptors exist:  $\beta_1$ -receptors are mainly located in the heart<sup>21</sup>;  $\beta_2$ -receptors in the lungs, gastrointestinal tract, blood vessels, and skin (keratinocytes, fibroblasts)<sup>22-25</sup>; and  $\alpha_1$ -receptors are, among other locations, found in the smooth muscles of cutaneous blood vessels. In rosacea,  $\beta$ -blockers are believed to reduce erythema by blocking  $\beta_2$ -adrenergic receptors on smooth muscles of cutaneous arterial blood vessels, causing vasoconstriction.<sup>26</sup> Moreover, they may reduce anxiety and tachycardia, which can exacerbate flushing reactions.<sup>27-30</sup>

The aim of this systematic review was to elucidate the efficacy of oral  $\beta$ -blockers for flushing and persistent facial erythema in rosacea and to provide recommendations for clinical practice.

## MATERIALS AND METHODS

The study protocol was registered in PROSPERO (identification 159025).<sup>31</sup> A systematic literature search following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines<sup>32</sup> was conducted in PubMed, Embase, Cochrane Library, and Web of Science. Search terms were *rosacea*, *flushing*, *facial erythema*, and *beta-blockers*, along with all possible synonyms. Oral  $\beta$ -blocker types were extracted from a recent Cochrane review<sup>33</sup> and by exploring their Medical Subject Heading terms.

Search strategy details can be found in Supplemental Table I (available via Mendeley at <https://doi.org/10.17632/36hgnt59n.1>). We included studies conducted in adults with cutaneous facial rosacea that provided original data on use of oral  $\beta$ -blockers for rosacea-associated flushing and/or erythema (Supplemental Table II; available via Mendeley at <https://doi.org/10.17632/36hgnt59n.1>). Physical modalities such as laser therapy also act on the vascular component but were beyond the scope of this article.<sup>3,34</sup>

All databases were searched to include published studies from date of inception until November 20, 2019. Titles and abstracts were screened for relevance by 2 independent reviewers (JGML and JIO). Next, full texts were critically assessed for eligibility by the same reviewers. Missing full texts were requested via the Radboud University Medical Library. In both phases, differences between the reviewers regarding inclusion were resolved by discussion. Excluded were articles involving patients younger than 16 years; ocular, extrafacial, or drug-induced rosacea; drug-induced flushing; in vitro and animal studies; studies in languages other than English, German, or Dutch; meta-analyses, (systematic) reviews, and abstracts of congresses, or those with unavailable full texts. The reference lists of included articles were checked for relevant articles not identified by the initial search.

Extracted study characteristics included study design; number of participants; rosacea symptoms;  $\beta$ -blocker type, dose, and treatment duration; erythema/flushing assessment method; study findings; and adverse events. A narrative synthesis was conducted for each  $\beta$ -blocker separately. Risk of bias was assessed by 2 reviewers (JGML and JIO), with disagreements resolved by discussion. The Cochrane Risk of Bias tool was used for assessment of risk of bias in randomized controlled trials (RCTs), with studies graded as having low, high, or unclear risk of bias.<sup>35</sup> For case-control studies, the Newcastle-Ottawa Scale was used.<sup>36</sup> For cohort studies without a control group (including case reports and case series), the Quality in Prognosis Studies tool was used.<sup>37</sup> For the Quality in Prognosis Studies, the overall risk of bias for each of the studies was judged as (1) low, if there was a low risk of bias

## CAPSULE SUMMARY

- Because treatment of rosacea-associated facial erythema and flushing is challenging, new therapeutic options are being explored.
- Beta-blockers may reduce erythema by vasoconstricting cutaneous vessels.
- Nonselective beta-blockers seem promising in treating erythema and flushing in rosacea that does not respond to conventional therapy, with most evidence available for carvedilol and propranolol.

**Abbreviations used:**

CI:	confidence interval
OR:	odds ratio
RCT:	randomized controlled trial

in all key domains; (2) unclear, if there was an unclear risk of bias for 1 or more key domains; and (3) high, if there was a high risk of bias for 1 or more key domains.

**RESULTS**

In total, 1941 articles were identified (Fig 1). After duplicate removal, 1544 articles were screened, resulting in inclusion of 25 abstracts eligible for full-text screening. Finally, 9 articles were included in this systematic review. Investigated  $\beta$ -blockers were carvedilol (n = 4),<sup>26,38-40</sup> propranolol (n = 3),<sup>29,41,42</sup> nadolol (n = 1),<sup>30</sup> and  $\beta$ -blockers in general (n = 1).<sup>43</sup> Among the included articles were 1 RCT, 1 cohort study, 1 case-control study, 3 case reports, and 3 case series. In the following sections and in Tables I and II, the  $\beta$ -blockers included in this review are presented separately.

**Nadolol**

Nadolol is a nonselective  $\beta$ -blocker, blocking both  $\beta_1$ - and  $\beta_2$ -adrenergic receptors. Its use was described in 1 RCT.<sup>30</sup>

Fifteen patients with rosacea with erythema and flushing received nadolol 40 mg once daily or twice daily, or placebo, during 53 days. During this period, flushing challenges using warm water, ethanol, and nicotinic acid were performed. The intensity of flushing reactions was measured as degree of skin perfusion by using laser Doppler velocimetry. No statistically significant differences in skin perfusion index were seen between nadolol and placebo. A modest significant subjective improvement in the number of occurrences, duration, and intensity of flushing with nadolol was found in 60% of patients; however, slight to definite worsening of flushing with nadolol was seen in 13% of patients as well.

**Carvedilol**

Carvedilol is a nonselective  $\beta$ -blocker with additional weak  $\alpha_1$ -blocking activity. Four publications describing use of carvedilol in rosacea were identified.<sup>26,38-40</sup>

In a retrospective case study, 5 patients with moderate/severe rosacea-associated flushing or persistent erythema were treated with carvedilol titrated up to 12.5 mg twice daily for 6 months or longer.<sup>39</sup> All patients observed a reduction in facial

erythema after 2 to 7 days from the start of treatment, and clinical erythema scores decreased in all patients at 6 months of treatment or longer. Erythema and facial flushing were still provoked by known triggers but to a much lower degree.

In another case series, carvedilol (3.125-6.25 mg, 2 or 3 times daily) was added to the regular medication (doxycycline, oral antihistamines/corticosteroids) of 11 patients with persistent erythema and facial flushing, and the dose was gradually titrated up to 31.25 mg/day.<sup>26</sup> This resulted in significant clinical erythema improvement within 3 weeks (range, 3-21 days) from the start of carvedilol, together with reduced cheek temperature and a large reduction in patient-assessed symptoms. Moreover, carvedilol allowed concurrent medications to be decreased in dosage or stopped.


Additionally, carvedilol usage was described in 2 case reports.<sup>38,40</sup> Clinical and patient-assessed improvements in erythema and flushing were seen within 2 weeks of carvedilol treatment of 6.25 mg 2 or 3 times daily, with increased improvement thereafter using maintenance therapy of 6.25 mg 1 to 3 times daily for 23 months. Moreover, only 6.25 mg daily was needed in the summer.<sup>38</sup> Lee et al<sup>40</sup> showed clinical reduction of erythema and flushing after the start of carvedilol (6.25-12.5 mg thrice daily) together with brimonidine gel. Dermoscopy showed polygonal vessel disappearance and blood vessel vasoconstriction after several months of starting carvedilol. Carvedilol was needed only intermittently afterward during summer.

**Propranolol**

Propranolol is a traditional nonselective  $\beta$ -blocker; 3 studies focused on its use in rosacea.<sup>29,41,42</sup>

In a retrospective cohort study, 9 patients with facial erythema and flushing received propranolol 10 mg 3 times daily, with doses increased as tolerated until symptoms improved, which appeared to be 20 to 40 mg 2 or 3 times daily.<sup>29</sup> Eight patients reported diminished symptoms and fewer flushing episodes while taking propranolol (duration of onset not described); 1 patient did not experience improvement but received only 100 mg thrice daily during 1 month without adverse effects and elected to discontinue propranolol thereafter.

Park et al<sup>42</sup> studied treatment with propranolol 10 mg thrice daily during 12 weeks in 22 patients with papulopustular and erythematotelangiectatic rosacea, and compared this with doxycycline (n = 15) and doxycycline and propranolol combination therapy (n = 26).<sup>42</sup> The propranolol group showed a significant faster and larger reduction in



**Fig 1.** Flow chart: article selection process.

clinical flushing scores compared to the other groups.

Finally, erythema and flushing improvement was observed in 1 patient already after 1 week of treatment with propranolol 40 mg once daily combined with minocycline and tranexamic acid.<sup>41</sup>

### **$\beta$ -blockers in general**

One study evaluated the association of  $\beta$ -blockers and the risk of developing rosacea by performing a case-control study with 53,927 patients with rosacea and 53,927 control individuals.<sup>43</sup> The article does not describe which  $\beta$ -blocker types were included. A marginal decreased risk (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.86-0.95) for current and long-term users of all  $\beta$ -blockers (OR, 0.89; 95% CI, 0.82-0.96) was found. Sensitivity analysis of the 3 most prescribed  $\beta$ -blockers in the United Kingdom (propranolol, atenolol, and bisoprolol) showed that

the risk was slightly decreased for current users of atenolol (OR, 0.83; 95% CI, 0.74-0.94) and for current long-term users of bisoprolol (OR, 0.76; 95% CI, 0.60-0.96). Unexpectedly, no decreased risk for developing rosacea among propranolol users was found.

### **Adverse events**

Seven included studies reported about adverse event occurrence (Table II).<sup>26,29,30,38,39,41,42</sup> For nadolol, decreased heart rate and blood pressure was seen in 100% and 93% of patients, respectively.<sup>30</sup> For carvedilol, treatment was discontinued in 9.1% of patients (1 in 11) due to hypotension,<sup>26</sup> and dosage was adjusted in 20% of patients (1 in 5) because of vertigo and nausea.<sup>39</sup> Additionally, feeling of weakness (1 in 5)<sup>39</sup> and decreased blood pressure (1 in 11)<sup>38</sup> were noticed during carvedilol treatment. For propranolol, treatment was discontinued in 22% of patients (2 in 9) because of dizziness, bradycardia,

**Table I.** Summary of included studies evaluating the efficacy of  $\beta$ -blockers in patients with rosacea with flushing and persistent facial erythema

Authors	Study design	Participants, n	Rosacea symptoms	Treatment (type, dose, duration)	Erythema/flushing assessment	Study findings	AEs
Wilkin <sup>30</sup>	RCT	15 (F: 11, M: 4; age range: 41-60 y)	ETR with flushing, erythema, telangiectasia	Study periods: A: 18 days, B: 17 days, C: 18 days Four groups: Group 1 (n = 4): A + B = placebo, C = nadolol 40 mg QD Group 2 (n = 3): A + B = placebo, C = nadolol 40 mg BID Group 3 (n = 4): A = nadolol 40 mg QD, B + C = placebo Group 4 (n = 4): A = nadolol 40 mg BID, B + C = placebo Flushing challenges: water (60°C), ethanol, nicotinic acid at days 14 + 18 of period A + C	Blood pressure, heart rate, laser Doppler velocimetry at right malar area for skin perfusion, patient perception (flushing number, duration, intensity)	No statistically significant differences in perfusion index values between nadolol and placebo during flushing challenges. Modest to significant subjective improvement on spontaneous flushing with nadolol in 9 of 15 patients; slight to definite worsening of spontaneous flushing with nadolol in 2 of 15 patients.	Lower heart rate with nadolol ( $61 \pm 2.5$ beats/min) than placebo ( $70 \pm 2.5$ beats/min) in all patients Lower mean arterial pressure with nadolol ( $76 \pm 2.5$ mm Hg) than placebo ( $80 \pm 2.5$ mm Hg) in 14 of 15 patients
Pietschke and Schaller <sup>39</sup>	Retrospective case study	5 (F: 3, M: 2; age range: 26-59 y)	Severe frequent flushing or persistent erythema	Carvedilol titrated up to 12.5 mg BID for $\geq 6$ months	Clinicians erythema assessment (CEA), patient assessment (patient self-assessment [PSA]), level of satisfaction, level of embarrassment	All patients observed reduced facial erythema after 2 to 7 days of treatment. Mean CEA decreased from 3.4 at baseline to 0.4 after $\geq 6$ months of treatment. Mean PSA decreased from 3.8 at baseline to 0.8 after $\geq 6$ months of treatment. All 5 patients were satisfied or highly satisfied with impact of carvedilol, with decreased level of embarrassment (from 3.4 to 0 after $\geq 6$ months).	Vertigo and nausea (n = 1) Feeling of weakness (n = 1)

Hsu and Lee <sup>26</sup>	Case series	11 (F: 9, M: 2; age range: 17-47 y)	Facial erythema	Carvedilol 3.125-6.25 mg BID or TID, titrated up to 31.25 mg/day, for 1 week to 28 months	Clinical photographs, cheek temperature, patient assessment (VAS)	Significant clinical improvement within 3 weeks (range, 3-21 days; mean, 10.5 days), mean reduction of cheek temperature of 2.2°C, mean reduction of 6.3 on VAS scale	Hypotension (n = 1)
Hsu and Lee <sup>38</sup>	Case report	1 (F, 48 y)	Flushing, persistent erythema, telangiectasia	Carvedilol (6.25 mg BID) for 1 week, then 6.25 mg QD, BID, or TID for 23 months	Clinical (not further specified), cheek temperature, patient assessment (VAS), blood pressure	Dramatic improvement in erythema and telangiectasia within 2 weeks of treatment. Continuation of improvement with minimal erythema and only transient flushing episodes thereafter. Reduction in cheek temperature from 36.9°C to 30.0°C. Mean VAS reduction from 10 to 1.	Reduction in blood pressure from 130/70 to 110/60 mm Hg No bradycardia
Lee and Lee <sup>40</sup>	Case report	1 (F, 59 y)	ETR with transient and persistent erythema, telangiectasia	Carvedilol (6.25-12.5 mg TID; duration ND) and topical 0.33% brimonidine daily	Clinical (not further specified), dermoscopy	Clinical: persistent erythema resolved in 3 weeks after starting brimonidine. Only minimal telangiectasia at 6-month follow-up. Only mild flares over the 11 months. Dermoscopy: disappearance of polygonal vessels and significant vasoconstriction of larger blood vessels after months.	ND
Kwon et al <sup>41</sup>	Case report	1 (F, 37 y)	Flushing, persistent erythema, and marked telangiectasia	Propranolol (40 mg QD), minocycline (50 mg QD), and tranexamic acid (250 mg QD) for 1 month	Clinical (not further specified)	Noticeable improvement of erythema and subjective symptoms already after 1 week of treatment, persisting for 2 months.	No AEs

Continued

Table I. Cont'd

Authors	Study design	Participants, n	Rosacea symptoms	Treatment (type, dose, duration)	Erythema/flushing assessment	Study findings	AEs
Park et al <sup>42</sup>	Prospective cohort study	63 (F: 47, M: 16; age range: 16-76 y)	ETR or PPR with flushing	Propranolol 10 mg 3 TID (n = 22), doxycycline 100 mg BID (n = 15), propranolol 10 mg BID + doxycycline 100 mg BID (n = 26) Duration: 12 weeks	Investigator Global Assessment (IGA), rosacea clinical score (ARCS), Patient Global Assessment (PGA)	Decrease of IGA, ARCS, and PGA in all 3 groups with no statistically significant differences. Propranolol group: flushing scores showed the biggest and fastest decrease after 12-week treatment compared to the other groups (statistically significant).	Propranolol-related: dyspepsia and headache (n = 1)
Craige and Cohen <sup>29</sup>	Retrospective cohort study	9 (F: 8; M: 1; age range: 31-69 y)	Facial erythema, flushing	Propranolol (10 mg TID) with doses increased as tolerated until symptoms improved	Patients' perceptions (flushing episodes, symptoms, quality of life)	8 of 9 patients: diminished symptoms and flushing episodes. None had sufficient relief from 10 mg TID. Dose needed to control flushing: 20-40 mg BID or TID. 1 patient: no improved flushing, only received 10 mg TID for 2 month, elected to discontinue thereafter.	Bradycardia, fatigue, dizziness (n = 1) Dizziness and sensation of balance loss (n = 1) Mild weight gain (n = 1) Decreased migraine headache severity (n = 2)
Spoendlin et al <sup>43</sup>	Case-control study	53,927 case patients, 53,927 control individuals	Rosacea (PPR and ETR)	$\beta$ -blockers in general	ND	Slightly decreased OR in current (OR, 0.91) and long-term $\beta$ -blocker users (OR, 0.89). Slightly decreased OR during current use of atenolol across all strata of exposure duration (OR, 0.74-0.83) and long-term current use of bisoprolol (OR, 0.76). No decreased OR for propranolol use.	ND

AE, Adverse event; BID, twice daily; ETR, erythematotelangiectatic rosacea; F, female; M, male; ND, not described; OR, odds ratio; PPR, papulopustular rosacea; QD, once daily; RCT, randomized controlled trial; RR, blood pressure; TID, thrice daily; VAS, Visual Analog Scale.

**Table II.** Reported adverse events in patients with rosacea treated with oral  $\beta$ -blockers for flushing and persistent facial erythema

Treatment	Reported adverse events
Nadolol	Decreased heart rate (n = 15), <sup>30</sup> decreased blood pressure (n = 14) <sup>30</sup>
Carvedilol	Hypotension (n = 1), <sup>26</sup> decreased blood pressure (n = 1), <sup>38</sup> vertigo and nausea (n = 1), <sup>39</sup> feeling of weakness (n = 1) <sup>39</sup>
Propranolol	Dizziness (n = 2), <sup>29</sup> decreased migraine headache severity (n = 2), <sup>29</sup> dyspepsia (n = 1), <sup>42</sup> headache (n = 1), <sup>42</sup> bradycardia (n = 1), <sup>29</sup> sensation of balance loss (n = 1), <sup>29</sup> weight gain (n = 1), <sup>29</sup> fatigue (n = 1) <sup>29</sup>

and balance loss sensation.<sup>29</sup> Other reported, acceptable, side effects were decreased migraine headache severity (2 in 9), weight gain (1 in 9), fatigue (1 in 9), dyspepsia (1 in 22), and headache (1 in 22).<sup>29,42</sup> The case report from Kwon et al<sup>41</sup> reported no adverse events during treatment with propranolol.

### Risk of bias

The number of patients of most studies was small, including multiple case series/case reports. Although the RCT was double-blinded, no information about the allocation sequence and blinding procedure was given (Supplemental Fig 1; available via Mendeley at <https://doi.org/10.17632/36hgynt59n.1>). In the case-control study, results could be biased by the copresence of papules and pustules and not solely erythema and flushing. For cohort studies, which were mostly retrospective, the domains *outcome measurement* and *study confounding* carried the highest risk of bias (Supplemental Fig 2; available via Mendeley at <https://doi.org/10.17632/36hgynt59n.1>). It was often not stated how and by whom the outcome measurements were determined. Moreover, potential confounders such as co-medication, rosacea type, cutaneous comorbidity, and rosacea-aggravating triggers were often insufficiently described or not taken into account.

### CONCLUSIONS

Diminishing erythema and flushing in rosacea is challenging, because it hardly responds to conventional anti-inflammatory treatment. Patients in the included studies often had an extensive history of ineffective topical, oral, and/or physical treatments. Most studies showed improved erythema and flushing after initiation of oral  $\beta$ -blockers. The evidence was highest for carvedilol and propranolol, 2 nonselective  $\beta$ -blockers. Unfortunately, only a small selection of available  $\beta$ -blocker types was examined.

The most common adverse effects of nonselective  $\beta$ -blockers are bradycardia, hypotension, bronchospasm, dizziness, somnolence, and fatigue.<sup>20,44</sup> One should be aware that  $\beta$ -blockers may exacerbate asthma and psoriasis.<sup>45-47</sup> Contraindications to

$\beta$ -blockers are congestive heart failure, cardiogenic shock, sinus bradycardia of less than 50 beats/minute, atrioventricular block, hyperactive airway disease, and Raynaud disease.<sup>19</sup> It is important to monitor patients for adverse effects, especially blood pressure and heart rate.<sup>38</sup>

Compared to other nonselective  $\beta$ -blockers, carvedilol and propranolol possibly have additional antioxidant and anti-inflammatory actions.<sup>26,40,48,49</sup> This may be beneficial in rosacea treatment, because reactive oxygen species released by inflammatory cells may play a role in disease development.<sup>50-52</sup> Carvedilol is usually well tolerated, even in elderly patients with heart failure.<sup>53</sup> Additionally, it results in fewer adverse effects, such as hypotension and bradycardia, than traditional  $\beta$ -blockers, which may be a limiting factor in normotensive patients.<sup>38,54</sup> Propranolol can cause additional diarrhea, nausea, and sexual dysfunction in men,<sup>55</sup> and it is recommended that it be started at a lower dosage in geriatric patients and those with renal or hepatic disease.<sup>20</sup> Nadolol offers the advantage of a once-daily dose because of its long plasma half-life (14-24 hours).<sup>30</sup>  $\beta$ -blockers dosages for reducing facial erythema are generally lower compared to the maintenance dose needed in hypertension (nadolol: 40-80 mg vs 80-320 mg daily<sup>30</sup>; carvedilol: 6.25-37.5 mg vs 25 mg daily<sup>26,38-40</sup>; propranolol: 30-120 mg vs 160-320 mg daily<sup>29,41,42</sup>). The efficacy of topical  $\beta$ -blockers such as timolol, being effective in various vascular dermatoses,<sup>20</sup> has not yet been investigated in rosacea.

Several studies have investigated other systemic medications antagonizing erythema and flushing in rosacea. Clonidine, an  $\alpha_2$ -adrenergic agonist, did not suppress erythema and flushing.<sup>56,57</sup> Also, rilmenidine, a central hypotensive drug, did not improve facial flushing compared to placebo.<sup>58</sup> Ondansetron, a serotonin antagonist, improved persistent erythema and flushing in 2 patients.<sup>59</sup> Naloxone, an opioid receptor antagonist, reduced alcohol-induced flushing, but it has many adverse effects.<sup>60</sup> Otherwise, phentolamine, an  $\alpha$ -adrenergic antagonist, even increased blood flow during exercise in frequent



blushers.<sup>28</sup> The aforementioned medications, therefore, seem largely dissatisfying today.

The quality of included studies was relatively low, and interstudy outcome variability was large. It was not possible to perform a meta-analysis, because erythema and flushing were assessed by using a wide spectrum of mostly subjective clinical and patient-based scores, and method standardization was often missing. The evaluation of facial erythema by visual assessment alone lacks objectivity and precision, and it is prone to inter- and intraobserver variability.<sup>61-63</sup> This makes comparison of individual study outcomes challenging. Simple, standardized, and objective erythema and flushing assessment, such as spectrophotometry and computer-aided image analysis, are advisable.<sup>64</sup>

To conclude, oral nonselective  $\beta$ -blockers could be an effective treatment option for rosacea patients with persistent facial erythema and flushing. Currently, most evidence is available for carvedilol and propranolol. Large, prospective, clinical trials are warranted to validate the data of these small studies. Researchers should further focus on the determination of the optimal dosage, treatment duration, and long-term therapeutic effects for adequate treatment of erythema and flushing in rosacea.

We would like to thank A.H.J. Tillema for her contribution in developing the search strategy.

## REFERENCES

1. Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. *Br J Dermatol*. 2017;176:431-438.
2. Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. *J Am Acad Dermatol*. 2018;78:148-155.
3. van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. *Br J Dermatol*. 2019;181:65-79.
4. Steinhoff M, Schmelz M, Schaubert J. Facial erythema of rosacea—etiology, different pathophysiologies and treatment options. *Acta Derm Venereol*. 2016;96:579-586.
5. Charkoudian N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. *J Appl Physiol (1985)*. 2010;109:1221-1228.
6. Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. *J Invest Dermatol Symp Proc*. 2011;15:53-62.
7. Yamasaki K, Gallo RL. The molecular pathology of rosacea. *J Dermatol Sci*. 2009;55:77-81.
8. Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. *J Drugs Dermatol*. 2013;12:650-656.
9. Stein-Gold L, Kircik L, Draelos ZD, et al. Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: pooled analysis of the two phase 3, 29-day, randomized, controlled REVEAL trials. *J Drugs Dermatol*. 2018;17:1201-1208.
10. Okwundu N, Cline A, Feldman SR. Difference in vasoconstrictors: oxymetazoline vs. brimonidine. *J Dermatolog Treat*. 2019: 1-7.
11. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. *Br J Dermatol*. 2012;166:633-641.
12. Layton AM, Schaller M, Homey B, et al. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. *J Eur Acad Dermatol Venereol*. 2015; 29:2405-2410.
13. Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. *J Drugs Dermatol*. 2014;13:56-61.
14. Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. *J Am Acad Dermatol*. 2018;78:1156-1163.
15. Patel NU, Shukla S, Zaki J, et al. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. *Expert Rev Clin Pharmacol*. 2017;10:1049-1054.
16. Nicholson K, Abramova L, Chren MM, et al. A pilot quality-of-life instrument for acne rosacea. *J Am Acad Dermatol*. 2007;57: 213-221.
17. Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. *Br J Dermatol*. 2010;163:719-725.
18. Cline A, McGregor SP, Feldman SR. Medical management of facial redness in rosacea. *Dermatol Clin*. 2018;36:151-159.
19. Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. *Indian J Dermatol Venereol Leprol*. 2017;83:399-407.
20. Chen L, Tsai TF. The role of beta-blockers in dermatological treatment: a review. *J Eur Acad Dermatol Venereol*. 2018;32: 363-371.
21. O'Rourke ST. Antianginal actions of beta-adrenoceptor antagonists. *Am J Pharm Educ*. 2007;71:95.
22. Lindsay SL, Holmes S, Corbett AD, et al. Innervation and receptor profiles of the human apocrine (epitrichial) sweat gland: routes for intervention in bromhidrosis. *Br J Dermatol*. 2008;159:653-660.
23. Steinkraus V, Steinfath M, Korner C, et al. Binding of beta-adrenergic receptors in human skin. *J Invest Dermatol*. 1992;98: 475-480.
24. Pullar CE, Isseroff RR. Beta 2-adrenergic receptor activation delays dermal fibroblast-mediated contraction of collagen gels via a cAMP-dependent mechanism. *Wound Repair Regen*. 2005;13:405-411.
25. Gillbro JM, Marles LK, Hibberts NA, et al. Autocrine catecholamine biosynthesis and the beta-adrenoceptor signal promote pigmentation in human epidermal melanocytes. *J Invest Dermatol*. 2004;123:346-353.
26. Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker. *J Am Acad Dermatol*. 2012;67:491-493.

27. Layton A, Thiboutot D. Emerging therapies in rosacea. *J Am Acad Dermatol*. 2013;69:S57-S65.
28. Drummond PD. The effect of adrenergic blockade on blushing and facial flushing. *Psychophysiology*. 1997;34:163-168.
29. Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. *J Am Acad Dermatol*. 2005;53:881-884.
30. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. *J Am Acad Dermatol*. 1989;20:202-205.
31. PROSPERO: International prospective register of systematic reviews. Available at: <https://www.crd.york.ac.uk/prospero/>. Accessed February 14, 2020.
32. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
33. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2017;1:CD002003.
34. Hofmann MA, Lehmann P. Physical modalities for the treatment of rosacea. *J Dtsch Dermatol Ges*. 2016;14:38-43.
35. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
36. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed February 18, 2020.
37. Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. *Ann Intern Med*. 2013;158:280-286.
38. Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea. *Arch Dermatol*. 2011;147:1258-1260.
39. Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. *J Dermatolog Treat*. 2018;29:310-313.
40. Lee CN, Lee JY. Severe erythematotelangiectatic rosacea with cold wave-induced epidermal necrosis treated with carvedilol combined with brimonidine gel. *Dermatol Ther*. 2017;30(4):e12501.
41. Kwon HJ, Suh JH, Ko EJ, et al. Combination treatment of propranolol, minocycline, and tranexamic acid for effective control of rosacea. *Dermatol Ther*. 2017;30(3):e12439.
42. Park JM, Mun JH, Song M, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea. *J Dermatol*. 2015;42:64-69.
43. Spoenclin J, Voegel JJ, Jick SS, et al. Antihypertensive drugs and the risk of incident rosacea. *Br J Dermatol*. 2014;171:130-136.
44. Rebora A. The management of rosacea. *Am J Clin Dermatol*. 2002;3:489-496.
45. Tatu AL, Elisei AM, Chioncel V, et al. Immunologic adverse reactions of beta-blockers and the skin. *Exp Ther Med*. 2019;18:955-959.
46. Patakas D, Argiropoulou V, Louridas G, et al. Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways. *Thorax*. 1983;38:108-112.
47. Abel EA, DiCicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. *J Am Acad Dermatol*. 1986;15:1007-1022.
48. Arumanayagam M, Chan S, Tong S, et al. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. *J Cardiovasc Pharmacol*. 2001;37:48-54.
49. Mak IT, Weglicki WB. Potent antioxidant properties of 4-hydroxyl-propranolol. *J Pharmacol Exp Ther*. 2004;308:85-90.
50. Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: the cytokine and chemokine network. *J Invest Dermatol Symp Proc*. 2011;15:40-47.
51. Bakar O, Demircay Z, Yuksel M, et al. The effect of azithromycin on reactive oxygen species in rosacea. *Clin Exp Dermatol*. 2007;32:197-200.
52. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. *Adv Ther*. 2001;18:237-243.
53. Yebra-Yebra M, Recio J, Arevalo-Lorido JC, et al. [Safety and tolerance of beta-blocker treatment in elderly patients with heart failure. BETANIC study]. *Med Clin (Barc)*. 2010;134:141-145.
54. Schaller M, Schofer H, Homey B, et al. State of the art: systemic rosacea management. *J Dtsch Dermatol Ges*. 2016;14(Suppl 6):29-37.
55. Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. *Arch Sex Behav*. 1988;17:241-255.
56. Cunliffe WJ, Dodman B, Binner JG. Clonidine and facial flushing in rosacea. *Br Med J*. 1977;1:105.
57. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. *Arch Dermatol*. 1983;119:211-214.
58. Grosshans E, Michel C, Arcade B, et al. [Rilmenidine in rosacea: a double-blind study versus placebo]. *Ann Dermatol Venereol*. 1997;124:687-691.
59. Wollina U. The response of erythematous rosacea to ondansetron. *Br J Dermatol*. 1999;140:561-562.
60. Bernstein JE, Soltani K. Alcohol-induced rosacea flushing blocked by naloxone. *Br J Dermatol*. 1982;107:59-61.
61. Tan J, Liu H, Leyden JJ, et al. Reliability of Clinician Erythema Assessment grading scale. *J Am Acad Dermatol*. 2014;71:760-763.
62. Hopkinson D, Moradi Tuchayi S, Alinia H, et al. Assessment of rosacea severity: a review of evaluation methods used in clinical trials. *J Am Acad Dermatol*. 2015;73:138-143.e4.
63. Bamford JT, Gessert CE, Renier CM. Measurement of the severity of rosacea. *J Am Acad Dermatol*. 2004;51:697-703.
64. Logger JGM, de Vries FMC, van Erp PEJ, et al. Noninvasive objective skin measurement methods for rosacea assessment: a systematic review. *Br J Dermatol*. 2020;182:55-66.